Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 5;17(4):R169.
doi: 10.1186/cc12848.

A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia

Free PMC article

A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia

Maiara Marx Luz Fiusa et al. Crit Care. .
Free PMC article

Abstract

Introduction: Endothelial barrier breakdown is a hallmark of septic shock, and proteins that physiologically regulate endothelial barrier integrity are emerging as promising biomarkers of septic shock development. Patients with cancer and febrile neutropenia (FN) present a higher risk of sepsis complications, such as septic shock. Nonetheless, these patients are normally excluded or under-represented in sepsis biomarker studies. The aim of our study was to validate the measurement of a panel of microvascular permeability modulators as biomarkers of septic shock development in cancer patients with chemotherapy-associated FN.

Methods: This was a prospective study of diagnostic accuracy, performed in two distinct in-patient units of a university hospital. Levels of vascular endothelial growth factor A (VEGF-A), soluble fms-like tyrosine kinase-1 (sFlt-1) and angiopoietin (Ang) 1 and 2 were measured after the onset of neutropenic fever, in conditions designed to mimic the real-world use of a sepsis biomarker, based on our local practice. Patients were categorized based on the development of septic shock by 28 days as an outcome.

Results: A total of 99 consecutive patients were evaluated in the study, of which 20 developed septic shock and 79 were classified as non-complicated FN. VEGF-A and sFlt-1 levels were similar between both outcome groups. In contrast, Ang-2 concentrations were increased in patients with septic shock, whereas an inverse finding was observed for Ang-1, resulting in a higher Ang-2/Ang-1 ratio in patients with septic shock (5.29, range 0.58 to 57.14) compared to non-complicated FN (1.99, range 0.06 to 64.62; P = 0.01). After multivariate analysis, the Ang-2/Ang-1 ratio remained an independent factor for septic shock development and 28-day mortality.

Conclusions: A high Ang-2/Ang-1 ratio can predict the development of septic shock in cancer patients with febrile neutropenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart.
Figure 2
Figure 2
Vascular permeability-related biomarkers in FN patients. Serum concentrations of soluble fms-like tyrosine kinase-1 (sFlt-1), vascular endothelial growth factor-A (VEGF-A) and angiopoietin (Ang) -1 and Ang-2 in patients with non-complicated febrile neutropenia (FN) (n = 79) or septic shock (n = 20). Horizontal bars represent median values; Mann-Whitney test.
Figure 3
Figure 3
Ang-2/Ang-1 ratio in FN patients. Angiopoietin- (Ang)-2/Ang-1 ratio in patients with non-complicated febrile neutropenia (FN) (n = 79) or septic shock (n = 20). Horizontal bars represent median values; Mann-Whitney test.
Figure 4
Figure 4
Twenty-eight-day survival and septic shock development in high-risk FN patients. Kaplan-Meier estimates of 28-day (a) survival and (b) septic shock development of patients with febrile neutropenia (FN) according to angiopoietin (Ang)-2/Ang-1 ratio. The ratio was dichotomized by the median Ang-2/Ang-1 ratio (2.2) in all patients (right) or by an optimal cut-off level of 5.0 (left), defined by a receiver operator characteristic (ROC) analysis.

Comment in

Similar articles

Cited by

References

    1. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;17:223–226. doi: 10.1097/MCO.0b013e32832a7902. - DOI - PubMed
    1. Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, Jimenez E, Mohan A, Khan RA, Whittle J, Jacobs E, Nanchal R, Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators. Nationwide trends of severe sepsis in the 21st century (2000-2007) Chest. pp. 1223–1231. - PubMed
    1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;17:R15. doi: 10.1186/cc8872. - DOI - PMC - PubMed
    1. Moyer MW. New biomarkers sought for improving sepsis management and care. Nat Med. 2012;17:999. doi: 10.1038/nm0712-999. - DOI - PubMed
    1. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;17:539–541. doi: 10.1136/bmj.324.7336.539. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources